Clive Mean­well's new obe­si­ty biotech, Met­sera, un­veils ear­ly GLP-1 da­ta with an eye on Phase 3 next year

Met­sera, the well-fund­ed obe­si­ty biotech from Pop­u­la­tion Health Part­ners and ARCH Ven­ture Part­ners, has un­veiled its first clin­i­cal da­ta just a few months af­ter emerg­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER